Premium
Long‐Term Clinical Evaluation of an Adsorbent Column (BM–01) of Direct Hemoperfusion Type for (β 2 –Microglobulin on the Treatment of Dialysis‐Related Amyloidosis
Author(s) -
Gejyo F.,
Teramura T.,
Ei I.,
Arakawa M.,
Nakazawa R.,
Azuma N.,
Suzuki M.,
Furuyoshi S.,
Nankou T.,
Takata S.,
Yasuda A.
Publication year - 1995
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1995.tb02289.x
Subject(s) - hemoperfusion , beta 2 microglobulin , amyloidosis , dialysis , hemodialysis , medicine , adsorption , urology , gastroenterology , clinical efficacy , surgery , chemistry , organic chemistry
The clinical efficacy and safety of a β 2 –microglobulin (β 2 M) adsorbent column, BM–01, on the treatment of dialysis‐related amyloidosis were investigated in 7 hemodialysis patients for more than 6 months. The percent reduction of serum β 2 M was more than 60–70%, and the level at the end of each session was less than 10 mg/L in almost all patients. The amount of β 2 M removed was calculated as more than 200–300 mg/session. The results demonstrated that BM–01 performed very well for removing β 2 M, was capable of maintaining less than 25 mg/L of time average concentration (TAC) for β 2 M, and improved the clinical symptoms. Clinically severe side effects were not observed. We recommend that BM–01 should undergo further evaluation for its usefulness in the long‐term treatment of dialysis‐related amyloidosis, though treatment with the column may not be successful in preventing the onset of the disease.